Ignite Creation Date:
2025-12-25 @ 2:40 AM
Ignite Modification Date:
2026-02-26 @ 2:19 AM
Study NCT ID:
NCT02495233
Status:
TERMINATED
Last Update Posted:
2024-11-27
First Post:
2015-07-08
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
Sponsor:
Astellas Pharma Global Development, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-09-08
Start Date Type:
ACTUAL
Primary Completion Date:
2016-09-28
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-09-28
Completion Date Type:
ACTUAL
First Submit Date:
2015-07-08
First Submit QC Date:
None
Study First Post Date:
2015-07-13
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-12-10
Results First Submit QC Date:
None
Results First Post Date:
2019-02-15
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2017-09-20
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2024-11-12
Last Update Post Date:
2024-11-27
Last Update Post Date Type:
ACTUAL